WeTrials

A Phase IB/II Study of Lorlatinib Combinations in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

What is this study?

This study is testing different combinations of targeted cancer medications for people with advanced lung cancer that has specific gene changes known as ALK or ROS1. Researchers want to find safer and more effective treatment options when previous therapies have stopped working.

Who can participate?

You may be able to join if you are 18 or older, have advanced non-small cell lung cancer with ALK or ROS1 gene changes, and your cancer has grown despite previous targeted treatments. There are some health rules regarding recent treatments, pregnancy, and pancreas health to keep you safe.

What will happen?

Participants will receive a combination of medications designed to target specific cancer genes, and your doctors will closely monitor your health and tumor size with regular imaging scans. You will need to review and sign a consent form before any study procedures begin.

Where and when?

The study locations include Boston, Massachusetts, and the current status of the study is not yet fully specified.

Key Points
  • 1Evaluates medication combinations for ALK or ROS1 positive lung cancer
  • 2Requires participants to be 18 or older with advanced non-small cell lung cancer
  • 3Involves regular monitoring and imaging scans to track tumor changes

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Lung CancerAnaplastic Lymphoma Kinase Gene TranslocationROS1 RearrangementRelapsed CancerMET AmplificationResistant CancerNSCLC

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.